Open AccessAll-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study
Author(s) -
Hanan Shawky,
Hesham Tawfik
Publication year - 2014
Publication title -
journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2014.08.001
Subject(s) - medicine , capecitabine , lapatinib , rash , tolerability , mucositis , adverse effect , nausea , oncology , metastatic breast cancer , neutropenia , trastuzumab , breast cancer , gastroenterology , cancer , radiation therapy , toxicity , colorectal cancer
Approximately one-third of patients with advanced, HER2+ve breast cancer (BC) develop brain metastases (BMs). The aim of this study is to investigate efficacy and tolerability of the combination of lapatinib and capecitabine (LC) in HER2+ve BC patients with brain metastases (BCBM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom